Heparins enoxaparin

No concurrent anticoagulation therapy (i.e., enoxaparin, heparin, or warfarin)... 

Galacturonic acid or poly-galacturonic acid V-acetyl [Phe8(CH2—NH)Arg9] bradykinin Enoxaparin, heparin Cyclodextrins... 

Clinically important, potentially hazardous interactions with butabarbital, dalteparin, enoxaparin, heparin... 

The most extensively studied drugs for the prevention of VTE are unfractionated heparin (UFH), the low-molecular-weight heparins (LMWHs dalteparin, enoxaparin, and tinza-parin), fondaparinux, and warfarin.2 The LMWHs and fondaparinux provide superior protection against VTE when... 

Low-molecular-weight heparins (LMWHs) may be an alternative to UFH in STE ACS. Enoxaparin may produce a modest benefit over UFH in reducing the risk of death or nonfatal MI. Enoxaparin has not been studied in the setting of primary PCI. 

Low-molecular-weight heparin (average MW -5000) has a longer duration of action and needs to be given only once daily (e.g., certoparin, dalteparin, enoxaparin, reviparin, tinzaparin). 

Approximate anti-Factor Xa activity of 100 units/1 mg enoxaparin sodium (with reference to the WHO First International Low Molecular Weight Heparin Reference Standard). 

LMWH is available for subcutaneous administration as enoxaparin (Lovenox), dalteparin (Fragmin), ardeparin (Normiflo), and tinzaparin (Innohep). Dana-paroid (Orgar an), a heparinoid composed of heparin sulfate, dermatan sulfate, and chondroitin sulfate, has greater factor Xa specificity than LMWH. Bleeding due to danaparoid is not reversed by protamine. 

Heparins, low molecular weight (LMWH) dalteparin sodium enoxaparin sodium nadroparin calcium tinzaparin sodium... 

The clinically used low molecular weight heparins are enoxaparin, reviparin, dalteparin, nadroparin, ardeparin and tinzaparin etc. 

Heparin and heparin-like polyanions are known to have significant stabilizing effects on proteins. Heparin itself has been used as a constituent of the solution used to reconstitute lyophilized proteins (54) while enoxaparin is a low molecular weight... 

Low molecular-weight heparins -parin Dalteparin, enoxaparin Anticoagulants (25)... 

Prophylactic enoxaparin is given subcutaneously in a dosage of 30 mg twice daily or 40 mg once daily. Full-dose enoxaparin therapy is 1 mg/kg subcutaneously every 12 hours. This corresponds to a therapeutic anti-factor Xa level of 0.5—1 unit/mL. Selected patients may be treated with enoxaparin 1.5 mg/kg once a day, with a target anti-Xa level of 1.5 units/mL. The prophylactic dose of dalteparin is 5000 units subcutaneously once a day therapeutic dosing is 200 units/kg once a day for venous disease or 120 units/kg every 12 hours for acute coronary syndrome. The use of LMW heparins is discouraged or contraindicated in patients with renal insufficiency or body weight greater than 150 kg. 

Oral combination product (Aggrenox) 200 mg extended-release dipyridamole plus 25 mg aspirin Enoxaparin (low-molecular-weight heparin, Lovenox)... 

Efficacy and safety oftenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001 358 605. LincoffAM, Califf RM, Van De WerfE etal. Mortality at I year with combination platelet glycoprotein llb/llla inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction GUSTO V randomized trial. JAMA 2002 288 2130. 

Cohen M. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein llb/llla blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes, J Invasive Cardiol 2000 I2(suppl E) E5-E9 discussion E25-E28,... 

Blazing MA, de Lemos JA, White HD, et al., for the A to Z Investigators, Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin A randomized controlled trial. JAMA 2004 292 55-64,... 

---